Brendan Delaney, the CEO of Aadi Bioscience, has resigned from his position, according to a company announcement. The resignation was effective immediately, and Aadi Bioscience’s board of directors has appointed Dr. Dean S. Collier as the interim CEO while the company searches for a permanent replacement.
Aadi Bioscience is a biopharmaceutical company that focuses on the development of precision medicines for the treatment of rare diseases. The company’s lead product, ABI-009, is currently being evaluated in clinical trials for the treatment of advanced solid tumors.
The reason for Delaney’s resignation was not disclosed, and the company did not provide any further details on the matter. However, the announcement stated that Delaney’s departure was not related to any disagreement with the company’s operations, policies, or practices.
In a statement, Aadi Bioscience’s board of directors thanked Delaney for his contributions to the company and wished him well in his future endeavors. The board also expressed its confidence in Dr. Collier’s ability to lead the company during the transition period.
Dr. Collier has more than 25 years of experience in the pharmaceutical industry, including executive positions at Novartis, Pfizer, and Johnson & Johnson. He has served on Aadi Bioscience’s board of directors since 2020 and has extensive experience in drug development and commercialization.
Aadi Bioscience’s lead product, ABI-009, is a protein-bound chemotherapy drug that targets tubulin, a protein involved in cell division. The drug has shown promising results in clinical trials, and Aadi Bioscience is currently exploring its potential in the treatment of several types of cancer.
In conclusion, the resignation of Aadi Bioscience’s CEO Brendan Delaney has created a leadership vacuum at the company, but the board’s appointment of Dr. Dean S. Collier as the interim CEO is a positive step towards ensuring business continuity. With the ongoing clinical trials of ABI-009, Aadi Bioscience’s focus on developing precision medicines for the treatment of rare diseases remains unchanged, and the company’s future prospects continue to be promising.
